PatientsVille.com Logo

RENAL FAILURE ACUTE and Lorazepam

PatientsVille

RENAL FAILURE ACUTE Symptoms and Causes

Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure.

If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for RENAL FAILURE ACUTE

RENAL FAILURE ACUTE treatment research studies

Lorazepam clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lorazepam Side Effects

Completed Suicide (220)
Somnolence (138)
Poisoning (137)
Suicide Attempt (121)
Overdose (105)
Anxiety (104)
Agitation (100)
Tachycardia (84)
Cardiac Arrest (81)
Confusional State (80)
Nausea (79)
Respiratory Arrest (73)
Dizziness (70)
Coma (68)
Sopor (68)
Hypotension (66)
Fall (66)
Toxicity To Various Agents (65)
Intentional Overdose (64)
Dyspnoea (61)
Fatigue (57)
Vomiting (56)
Depression (56)
Insomnia (56)
Cardio-respiratory Arrest (55)
Death (55)
Sedation (52)
Headache (49)
Loss Of Consciousness (48)
Asthenia (45)
Convulsion (45)
Diarrhoea (43)
Metabolic Acidosis (42)
Condition Aggravated (39)
Tremor (37)
Pyrexia (34)
Product Substitution Issue (34)
Unresponsive To Stimuli (34)
Suicidal Ideation (33)
Psychotic Disorder (33)
Feeling Abnormal (33)
Catatonia (33)
Pain (33)
Gait Disturbance (32)
Disorientation (31)
Respiratory Failure (31)
Syncope (30)
Malaise (30)
Depressed Level Of Consciousness (29)
Oxygen Saturation Decreased (29)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Feeling apathetic, lack of interest in anything. Not sure if it is my emotional state or because of lorazepam

Hi, i was on loraezpam for anxiety attacks and was having some side affects off of it and stopped taking it.i was taking it for about a month or less. it made me feel more depressed then i was. how long does it take to get out of the system?

i had heart failure last august 2010, among other tablets i have been taking emconcor. i wonder whether these tablets are responsible for making my limbs feel weak, and lightheaded.

i am taking aprove tab 150 daily becoz of renal failur one year age ,i read about aprovel side effect.i am afried to of side effect. and my b.b in normal rang

<b>Describe Your Tazocin Experience Here:</b>after it was administered to my farther in hospital for the first time on day he was due to be released he had a cardiac arrest with multiple organ failure and subsequently died

had my first shot of aranesp one week ago for anemia , i have renal failure, I'm 62 , and I am a working nurse. I will be getting aranesp every 2 weeks if my blood count is less than 11. well out of no where I have becom

i am from India my father who has been suffering from renal problem. i consulted a nephrology who advised me to take wysolone tab. now my father has been suffering from loose motion(sever loose motion). he can'

<span style='color: #808080;'><b>Describe Your Injection site swelling from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: I am 46, Female on discharge from hospital 12.6.10 10pm after treatment for acute diverticuli

<span style='visibility: visible;'><span style='visibility: visible;'>After battling with acute insomnia for about 3 months, my GP prescribed Trimipramine 25mg. This still didn't get me much sleep, so he prescribed Purata 30mg. Better, bu

5th Week of Champix, so not smoked now for 3 weeks. Have experienced really bad headaches, mainly in the eyes, like acute sinisitus, will have to go to doctors to see if being caused by champix. Hope I do not have to come off them

A report-I had a suppression dose of Macrobid; after 8 months much worse and after a year in fulminant hepatic failure leading to a transplant. How can these changes be spotted for women like me.

Acute lower back pain causing lack of mobility?

RENAL FAILURE ACUTE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Effect of Additive Lorazepam on Patient Satisfaction as a Premedication in Diagnostic Flexible Bronchoscopy
Condition: Patient Satisfaction for Bronchoscopy
Interventions: Drug: Lorazepam;   Drug: Control
Outcome Measures: patient satisfaction;   relationship between patient satisfaction and sleep quality, anxiety level
2 Unknown  Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)
Condition: Healthy Subjects
Interventions: Drug: Lorazepam;   Drug: Placebo
Outcome Measures: Correlated Brain Activity using MEG and SNI analysis;   Correlated Brain Activity using MEG and standard analyses
3 Unknown  IM Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Agitation
Interventions: Drug: IM olanzapine;   Drug: haloperidol plus Lorazepam IM
Outcome Measures: Positive and Negative Symptom Scale Excited Component (PANSS-EC);   Agitation-Calmness Evaluation Scale (ACES)
4 Recruiting Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Lorazepam;   Drug: Placebo;   Drug: Haloperidol decanoate;   Behavioral: Questionnaires
Outcome Measure: Control of Delirium Symptoms
5 Recruiting Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
Conditions: Status Epilepticus;   Epilepsy
Interventions: Drug: Clonazepam;   Drug: Fosphenytoin;   Drug: Placebo;   Drug: Lorazepam
Outcome Measures: Percentage of patient with a cessation of seizures and absence of recurrence;   Duration between the first cessation and the recurrence of seizures;   Percentage of patients having had a second injection of benzodiazepine;   Percentage of patients having had an injection of the second line treatment;   Percentage of patients having a general anesthesia for refractory status epilepticus;   Percentage of patients having had a side effect;   Percentage of patients having been mechanically ventilated;   Glasgow Coma Scale;   Mortality;   Length of stay in Intensive Care Unit;   Length of stay in hospital
6 Recruiting The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
Condition: Alzheimer's Disease (AD)
Intervention: Drug: Lorazepam
Outcome Measures: AVLT Long term memory score;   Groton Maze Learning Test (GMLT) score
7 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly
Condition: Healthy Volunteers
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
8 Recruiting Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly
Condition: Volunteers Aged Between 65 and 75 Years Old
Interventions: Drug: etifoxine;   Drug: Lorazepam;   Drug: Placebo
Outcome Measure: Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)
9 Not yet recruiting Clobazam Use in Epilepsia Partialis Continua - Pilot Study
Conditions: Epilepsia Partialis Continua;   Kojewnikov's Epilepsy;   Epilepsy
Interventions: Drug: Clobazam;   Drug: Clonazepam;   Drug: Lorazepam
Outcome Measures: Time (measured in minutes) to onset of seizure freedom;   Reduction of seizure frequency/minute;   Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale;   Ambulatory function as measured by the Hauser Ambulation Index
10 Recruiting Characterizing and Predicting Drug Effects on Cognition
Condition: Cognitive Deficits
Interventions: Drug: Topiramate;   Drug: Lorazepam
Outcome Measures: Relationship between neurocognitive performance and study drug plasma concentration;   Neurophysiological effect of study drug on working memory
11 Recruiting Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)
Conditions: Liver Fibrosis;   Alpha-1 Antitrypsin Deficiency;   AAT Deficiency;   AATD
Interventions: Device: Abdominal ultrasound;   Procedure: History and physical;   Procedure: Intravenous catheter;   Procedure: Blood draw;   Other: Liver questionnaire;   Procedure: Liver Biopsy;   Drug: Midazolam;   Drug: Fentanyl;   Drug: Lidocaine;   Drug: Acetaminophen;   Drug: Lorazepam;   Drug: Oxycodone/Acetaminophen;   Drug: Ondansetron
Outcome Measures: To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency and a genotype of ZZ.;   To identify environmental and host risk factors for clinically significant liver fibrosis.;   To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.;   To explore epigenetic markers for the development of liver fibrosis.;   To quantify liver fibrosis progression.
12 Recruiting Sedative Premedication: Efficacy On Patient Experience
Condition: Perioperative Anxiety
Interventions: Drug: Lorazepam;   Other: no premedication;   Drug: Placebo (microcrystalline celluloses)
Outcome Measures: the EVAN score;   the perioperative level of anxiety
13 Not yet recruiting Explanation About Sleep in Post Trauma Patients
Conditions: Post Traumatic Stress Disorder;   Sleep Deprivation
Interventions: Behavioral: Explanation encouraging sleep;   Behavioral: Explanation discouraging sleep;   Drug: Lorazepam
Outcome Measure: PTSD severity as measured by CAPS
14 Recruiting Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability
Condition: Dental Care for Disabled
Interventions: Drug: Midazolam Mylan;   Drug: Lorazepam Mylan;   Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Outcome Measures: Level of cooperation of patient when receiving regular dental care;   Recording of vital parameters during regular dental care delivery;   Level of patient comfort and possible side-effects after dental treatment session
15 Recruiting A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865
Condition: Healthy
Interventions: Drug: PF-06372865 or Placebo;   Drug: PF-06372865 or Placebo or Lorazepam
Outcome Measures: Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Area Under the Curve From Time Zero to Extrapolated Infinite Time;   Apparent Oral Clearance (CL/F);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2);   Area Under the Curve From Time Zero to 24 hours;   Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy);   Change in Body Sway;   Change in Smooth Pursuit;   Change in Bond and Lader VAS;   Change in Adaptive Tracking;   Change in Visual Verbal Learning Test;   Change in Pharmaco-EEG
16 Unknown  Enteral Versus Intravenous Sedation in Critically Ill High-risk ICU Patients
Conditions: Critical Illness;   Mechanical Ventilation Complication
Interventions: Procedure: Enteral Sedation (EN);   Procedure: Control group: Intravenous Sedation (IV)
Outcome Measures: Percent of efficacy, measured by observed RASS = desired RASS ± 1.;   Sedation protocol effectiveness: percentage of "protocol violation days" on the total of ICU days.;   Delirium and coma free days (respectively negative CAM-ICU and RASS > - 3 in all daily observations until 28° ICU day) (11);   Ventilation free days (12);   Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance) (13);   Overall ICU and hospital mortality, absolute mortality after 1 year from ICU discharge.;   Sedative drugs costs.;   Indirect inefficacy markers
17 Recruiting Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Conditions: Alcohol Withdrawal Delirium;   Alcohol Withdrawal Associated Autonomic Hyperactivity;   Alcohol Withdrawal Hallucinosis;   Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine;   Drug: Placebo
Outcome Measures: The length of ICU stay defined as the time between randomization and ICU transfer orders.;   The number of delirium-free and ventilator-free days during the first 28 days of hospitalization;   The length in days of the hospital stay;   Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.;   Resource utilization costs associated with this hospitalization.;   Predefined adverse events;   average MINDS score
18 Not yet recruiting Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: Standard anti-emetics in conjunction with R-CHOP
Outcome Measures: Complete Response, Acute Phase (Day 1), Cycle 1;   Complete Response, Delayed Phase (Days 2 to 11), Cycle 1;   Complete Response - Cycle 2 and beyond;   No Significant Nausea - Cycle 2 and beyond;   Failure of standard anti-emetic prophylaxis, Day 1 to Day 11, Cycle 1 and beyond;   Frequency of common adverse events associated with anti-emetics;   Severity of common adverse events associated with anti-emetics
19 Recruiting TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation
Conditions: Cardiac Arrest;   Postanoxic Encephalopathy;   Status Epilepticus
Interventions: Drug: Anti-epileptic drugs;   Other: No anti-epileptic drugs
Outcome Measures: Neurological outcome;   Long term outcome
20 Unknown  Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression
Condition: Depression
Interventions: Device: Thrymatron System IV device (CONSOLIDATION ELECTROCONVUsLIVE THERAPY) plus PHARMACOTHERAPY;   Drug: PHARMACOTHERAPY
Outcome Measures: Hamilton Depression Rating Scale 21 items (HDRS-21);   Mini-Mental State Examination (MMSE 35);   UKU - Adverse effects rating scales;   Demographical Data Memory (MEDABI-20);   Rey Figure;   Trail Making Test A;   Trail Making Test B;   Stroop Test;   Direct and inverse digits (WAIS, Weschler Adults Intelligence Sacle).;   Vocabulary WAIS (Weschler Adults Intelligence Scale);   Frequency Hospitalization Quotient;   Hospital Day Quotient (HDQ)